Suchergebnisse - "Minassian, Angela M"

PubPharm (10)

1

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK : eight-month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Wright, A. | +59

2

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Heath, P. | Galiza, E. | Baxter, D. | +42

3

Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine

enthalten in: JCI insight | 2023

von Barrett, J. | Davis, C. | Fallon, J. | +21

4

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

enthalten in: Frontiers in immunology | 2023

von Barrett, J. | Silk, S. | Mkindi, C. | +18

5

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST) : a multicentre, blinded, phase 2, randomised trial

enthalten in: The Lancet. Infectious diseases | 2022

von Munro, A. | Feng, S. | Janani, L. | +153

CommentIn: Lancet Infect Dis. 2022 Aug;22(8):1092-1093. - PMID 35550263

6

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2022

von Liu, X. | Munro, A. | Feng, S. | +56

CommentIn: J Infect. 2023 Feb;86(2):154-225. - PMID 36509358

7

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) : a single-blind, randomised, controlled, phase 2/3 trial

enthalten in: Lancet (London, England) | 2021

von Ramasamy, M. | Minassian, A. | Ewer, K. | +162

ErratumIn: Lancet. 2021 Dec 19;396(10267):1978. - PMID 33341142

8

Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies

enthalten in: Cell reports. Medicine | 2021

von Willcox, A. | Huber, A. | Diouf, A. | +10

9

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1/2, single-blind, randomised controlled trial

enthalten in: Lancet (London, England) | 2020

von Folegatti, P. | Ewer, K. | Aley, P. | +130

CommentIn: Lancet Infect Dis. 2020 Jul;20(7):760-761. - PMID 32325036

10

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults : a phase I clinical trial

enthalten in: Human vaccines & immunotherapeutics | 2013

von Rowland, R. | Pathan, A. | Satti, I. | +16

1
[1]